Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Assets (2016 - 2025)

Altimmune (ALT) has disclosed Current Assets for 16 consecutive years, with $216.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 48.61% to $216.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $216.6 million, a 48.61% increase, with the full-year FY2024 number at $137.3 million, down 34.52% from a year prior.
  • Current Assets was $216.6 million for Q3 2025 at Altimmune, up from $188.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $245.2 million in Q1 2021 to a low of $137.3 million in Q4 2024.
  • A 5-year average of $189.7 million and a median of $191.1 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 518.59% in 2021, then plummeted 34.52% in 2024.
  • Altimmune's Current Assets stood at $204.1 million in 2021, then decreased by 5.54% to $192.8 million in 2022, then rose by 8.72% to $209.6 million in 2023, then tumbled by 34.52% to $137.3 million in 2024, then surged by 57.82% to $216.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Current Assets are $216.6 million (Q3 2025), $188.4 million (Q2 2025), and $155.3 million (Q1 2025).